Ishita Drugs & Indus Complete Financial Statements
In FY2026, Ishita Drugs & Indus (ISHITADR) reported revenue ₹15 Cr, net profit ₹1 Cr and EPS ₹2.60, with a net profit margin of 6.7% and ROE of 9.1%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Also explore ISHITADR share price history to track price trends across different timeframes.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
ISHITADR Revenue, Net Profit & EBITDA — Year-on-Year Growth
ISHITADR YoY (March 2025 vs March 2026). For live price, earnings ratios and company overview, see ISHITADR stock price BSE.
ISHITADR Income Statement — Revenue, EBITDA & Net Profit
Ishita Drugs & Indus revenue ₹15 Cr, EBITDA ₹1 Cr, net profit ₹1 Cr, EPS ₹2.60 (2026) — net profit margin 6.7%. Analyse Ishita Drugs & Indus ownership pattern to track promoter, FII and institutional holdings.
| Particulars | March 2026 | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15 | 15 | 16 | 12 | 14 | 14 | 15 | 9 | 7 | 7 | 7 | 8 |
| Expenses | 14 | 14 | 14 | 11 | 13 | 13 | 14 | 9 | 6 | 6 | 7 | 7 |
| EBITDA | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 |
| Operating Profit Margin % | 5.00% | 7.00% | 6.00% | 6.00% | 8.00% | 7.00% | 5.00% | 6.00% | 7.00% | 6.00% | 4.00% | 4.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Earnings Per Share (₹) | 2.60 | 2.90 | 2.50 | 1.93 | 2.69 | 2.77 | 1.83 | 1.18 | 0.83 | 0.61 | 0.46 | 0.74 |
ISHITADR Balance Sheet — Assets, Liabilities & Shareholders' Equity
ISHITADR total assets ₹16 Cr, total equity ₹11 Cr, total liabilities ₹ Cr (2025) — ROE 9.1%.
| Particulars | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Total Assets | 16 | 11 | 11 | 11 | 9 | 10 | 8 | 7 | 7 | 8 | 7 |
| Current Assets | 15 | 10 | 10 | 10 | 8 | 8 | 7 | 6 | 6 | 7 | 6 |
| Fixed Assets | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 4 | 3 | 3 | 4 | 3 | 5 | 4 | 3 | 3 | 2 | 2 |
| Other Assets | 12 | 7 | 7 | 6 | 5 | 3 | 3 | 3 | 4 | 5 | 4 |
| LIABILITIES | |||||||||||
| Total Liabilities | |||||||||||
| Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-Current Liabilities | |||||||||||
| SHAREHOLDERS' EQUITY | |||||||||||
| Total Equity | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 6 | 6 | 6 | 6 |
| Share Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves & Surplus | 8 | 7 | 6 | 6 | 5 | 4 | 3 | 3 | 3 | 3 | 3 |
ISHITADR Cash Flow Statement — Operating, Investing & Financing
Ishita Drugs & Indus operating cash flow ₹-4 Cr, investing ₹-1 Cr, financing ₹4 Cr, net cash flow ₹0 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -4 | 2 | -3 | 3 | -1 | 1 | 1 | 1 | 1 | 0 | 0 |
| Investing Activities | -1 | 0 | 1 | -1 | 3 | -1 | -1 | -1 | -1 | 0 | 0 |
| Financing Activities | 4 | -1 | 1 | 0 | 0 | 0 | 0 | 0 | -1 | 1 | 0 |
| Net Cash Flow | 0 | 1 | -1 | 2 | 2 | 0 | 0 | 0 | -1 | 1 | 0 |